Elanco EVP Rajeev Modi buys $99,938 of company stock
Rajeev A. Modi, Elanco's EVP U.S. Pet Health and Global Digital Transformation, purchased 4,911 shares of company stock for $99,938 on May 15, 2026. This transaction increased his direct ownership to 160,812 shares, despite the stock trading below its fair value and experiencing recent declines. The purchase follows Elanco's strong Q1 2026 financial results and the launch of new products, suggesting confidence in the company's future.
Elanco CEO Jeffrey Simmons buys $99,842 in company stock
Elanco Animal Health Inc. CEO Jeffrey N. Simmons purchased $99,842 worth of company common stock "indirectly through a revocable trust" on May 15, 2026, acquiring 4,971 shares at $20.085 per share. Following this transaction, the trust holds 171,971 shares and Simmons directly holds 2,051,898 shares. The company has recently reported strong first-quarter financial results, beating analyst expectations, and launched a new canine treatment.
Elanco (NYSE: ELAN) CEO adds shares and receives deferred units
Jeffrey N. Simmons, President and CEO of Elanco Animal Health (NYSE: ELAN), recently purchased 4,971 shares of common stock through a revocable trust at $20.085 per share, increasing indirect holdings to 171,971 shares. Additionally, he received 142.3429 deferred stock units, which represent the right to one common share or its cash equivalent, to be settled post-employment or in a specified future year. Following these transactions, Simmons directly holds over 2 million common shares and more than 24,000 deferred stock units.
Elanco (NYSE: ELAN) officer Modi buys shares and receives deferred stock units
Elanco Animal Health officer Rajeev A. Modi purchased 4,911 shares of common stock at $20.35 per share, increasing his direct holdings to 160,812 shares. He also received a grant of 74.3671 deferred stock units. These transactions were disclosed in a Form 4 SEC filing, indicating a positive sentiment surrounding the insider activity.
Elanco (NYSE: ELAN) CFO receives grant of deferred stock units as compensation
Elanco Animal Health's EVP and CFO, Robert M. VanHimbergen, was granted 9.9204 deferred stock units (DSUs) as part of his compensation, at a reference price of $19.86 per unit. This transaction increased his total DSU holdings to 84.4197 units. Each DSU represents the right to receive one share of common stock or its cash equivalent, settling after employment or in a specified future year under the company's Executive Deferral and Stock Match Plan.
Elanco Animal Health’s SWOT analysis: stock outlook amid growth targets
Elanco Animal Health (ELAN) has outlined a three-year strategic roadmap emphasizing mid-single-digit growth and significant margin expansion through its Ascend program. Analysts view the company's targets as achievable, potentially conservative, and its new product pipeline, including Befrena, as a key growth driver. While risks include execution challenges for margin expansion and conservative guidance potentially limiting near-term stock appreciation, the company's diversified business model and strong product pipeline offer upside potential.
Elanco Animal Health Launches Canine Dermatitis Drug Befrena
Elanco Animal Health has launched Befrena, a new drug for the treatment of canine dermatitis. This launch provides veterinarians with an innovative solution to manage chronic pruritus associated with allergic dermatitis and atopic dermatitis in dogs. The announcement was made following the U.S. Food and Drug Administration's approval of the drug.
New dog allergy shot from Elanco offers 6–8 weeks of itch relief
Elanco has launched Befrena (tirnovetmab), a new anti-IL-31 monoclonal antibody injection for canine allergic and atopic dermatitis, targeting the $1.3 billion U.S. veterinary dermatology market. This USDA-approved product provides 6-8 weeks of itch relief, with effects starting within 24 hours, and has no age or weight restrictions. Elanco is now the only pet health company with two USDA-approved mAb products, expanding its dermatology portfolio and offering a new treatment option for itchy dogs.
Elanco Animal Health’s SWOT analysis: stock outlook amid growth targets
Elanco Animal Health (NYSE:ELAN) has garnered analyst attention after outlining a three-year strategic roadmap emphasizing mid-single-digit growth and significant margin expansion through its Ascend program. The company, trading at $19.86 with a $9.92 billion market cap, expects high-single-digit growth in pet health and more modest growth in farm animals, with new product launches like Befrena poised to drive future revenue. While analysts view the targets as conservative, providing room for upside, challenges include execution risk for margin targets and potential limits to near-term stock appreciation due to the conservative outlook.
Elanco Launches Befrena™ (tirnovetmab), New Anti-IL-31 Monoclonal Antibody, a Breakthrough Addition to the $1.3 Billion U.S. Canine Dermatology Market
Elanco Animal Health has launched Befrena™ (tirnovetmab), a new anti-IL-31 monoclonal antibody for the treatment of canine allergic and atopic dermatitis. This injection, effective for 6 to 8 weeks and showing itch control within 24 hours, marks Elanco's second mAb product in the U.S. pet health market. It is being introduced through a phased launch, with positive results already noted from veterinarians participating in the Early Experience Program.
Elanco Animal Health (NYSE:ELAN) - Stock Analysis
Elanco Animal Health (NYSE:ELAN) is currently trading at US$19.86, which is 45.8% below its estimated fair value of US$28.77. Analysts expect Elanco's earnings to grow by 55.82% per year. The company recently exceeded Q1 2026 forecasts, showing strong product growth in both pet and farm animals, and raised its full-year 2026 guidance.
Elanco finalizes acquisition of AHV International
Elanco Animal Health has completed its acquisition of AHV International, a Dutch innovator in farm animal health, expanding Elanco's presence in the global dairy market. This acquisition will allow Elanco to offer an expanded portfolio of products to improve transition cow health, well-being, and productivity, enhancing dairy producers' ability to meet the rising global demand for milk. The deal aims to integrate AHV’s innovative tools, such as StopLac and Quorum Sensing Technology, to support animal welfare, sustainability, and reduce the need for antibiotics in dairy farming.
Dodge & Cox holds 13.9% of Elanco (NYSE: ELAN) in 13G/A amendment
Dodge & Cox has disclosed an updated beneficial ownership of 13.9% in Elanco Animal Health Inc (NYSE: ELAN) through a Schedule 13G/A amendment. This amounts to 68,944,100 shares as of March 31, 2026, with the Dodge & Cox Stock Fund alone holding 9.1% or 45,270,700 shares. The filing clarifies that this amendment reflects a passive investment and changes in holdings across client accounts rather than a direct open-market transaction.
Elanco to Participate in Upcoming Investor Conferences
Elanco Animal Health will participate in two upcoming investor conferences: the Stifel 2026 Jaws & Paws Conference on May 27 and the William Blair 46th Annual Growth Stock Conference on June 2. CEO Jeff Simmons and CFO Bob VanHimbergen will be presenting, discussing the company's strategic direction and market outlook. Live audio webcasts of these events will be available on Elanco's investor website.
How to listen in as Elanco execs talk to investors in May and June
Elanco Animal Health Incorporated (NYSE: ELAN) announced that its management will participate in two upcoming investor conferences. CEO Jeff Simmons and CFO Bob VanHimbergen will join a fireside chat at the Stifel 2026 Jaws & Paws Conference on May 27, 2026, and Simmons will present at the William Blair 46th Annual Growth Stock Conference on June 2, 2026. Live audio webcasts and limited-time replays will be available on Elanco's investor website.
Elanco to pay $6.75M to settle antitrust allegations involving flea and tick products
Elanco Animal Health Inc. and several retailers have agreed to a $9.275 million settlement in a class-action lawsuit. The lawsuit accused Elanco of engaging in anticompetitive practices by allegedly paying major pet retailers not to stock generic versions of its Advantix flea and tick products. Elanco's portion of the settlement is $6.75 million, and it also includes a five-year restriction on offering exclusive discounts for Advantix.
Elanco reaches $9.3M settlement with consumers over antitrust allegations involving flea and tick products
Elanco has agreed to a $9.3 million settlement with consumers to resolve antitrust allegations related to its flea and tick prevention products. While Elanco disputes the allegations, the settlement aims to resolve claims that the company used anti-competitive tactics. This development follows a period of scrutiny over the pharmaceutical industry's practices.
Primecap Management reports 9.22% stake in Elanco (ELAN)
PRIMECAP MANAGEMENT CO/CA/ has filed an amended passive investment disclosure (Schedule 13G/A) reporting a 9.22% beneficial ownership stake in Elanco Animal Health Incorporated (ELAN). This constitutes 45,840,956 shares of common stock, with sole voting power over 45,573,360 shares. The filing indicates a significant institutional holding but is a snapshot of position size rather than a transaction, and its full implications depend on any future filings or public statements.
Elanco Animal Health Incorporated (ELAN) Beats Q1 Earnings and Revenue Estimates
Elanco Animal Health Incorporated (ELAN) reported stronger-than-expected Q1 earnings of $0.4 per share, surpassing the Zacks Consensus Estimate of $0.34, and revenues of $1.37 billion, exceeding the estimate by 6.93%. Despite outperforming market expectations for earnings and revenue over the past four quarters, the stock has underperformed the S&P 500 year-to-date and currently holds a Zacks Rank #4 (Sell) due to unfavorable estimate revisions. Investors are advised to monitor management's commentary and future estimate changes, as the company belongs to an industry expected to underperform.
ELAN SEC Filings - Elanco Animal Health 10-K, 10-Q, 8-K Forms
This page provides access to Elanco Animal Health (ELAN) SEC filings, including annual 10-K, quarterly 10-Q, and material event 8-K reports, along with insider trading forms. It highlights recent 8-K filings detailing financial results, restructuring, credit amendments, and investor events. Stock Titan enhances this information with AI-powered summaries to help investors quickly understand the significance of each filing.
Elanco Animal Health 1Q Adj EPS 40c >ELAN
The article reports that Elanco Animal Health (ELAN) achieved an adjusted earnings per share of 40 cents in the first quarter.
Elanco Animal Health Price Target Raised to $31.00/Share From $30.00 by Citigroup
Citigroup has increased its price target for Elanco Animal Health (ELAN) to $31.00 per share from the previous $30.00. This adjustment by Citigroup indicates a slightly more optimistic outlook on the company's stock performance.
ELAN Maintained by Citigroup -- Price Target Raised to $31.00
Citigroup has maintained a 'Buy' rating for Elanco Animal Health (ELAN) and increased its price target from $30.00 to $31.00, signaling an optimistic outlook. Despite this, GuruFocus indicates ELAN is significantly overvalued at $24.01 compared to its GF Value™ of $14.39. The company shows strong momentum but poor valuation, suggesting caution for investors.
ELAN Maintained by JP Morgan -- Price Target Raised to $30
JP Morgan maintained an Overweight rating for Elanco Animal Health (ELAN) and raised its price target from $28.00 to $30.00, signaling a positive outlook. Despite this, the stock is currently trading at $24.01, significantly above its GF Value™ of $14.39, indicating it is 66.9% overvalued. While the company exhibits solid performance in key financial metrics with a GF Score™ of 71/100, its high valuation suggests caution for investors.
elan-20260331
This Form 10-Q filing from Elanco Animal Health Incorporated details their financial performance for the first quarter ended March 31, 2026. The company reported increased revenue across both pet health and farm animal segments, driven by higher volumes and pricing, and discussed strategic initiatives including the recent acquisition of AHV International B.V. and ongoing restructuring plans. Legal proceedings and risk factors impacting the company's financial condition are also outlined.
Elanco Animal Health Incorporated (NYSE:ELAN) Q1 2026 Earnings Call Transcript
Elanco Animal Health (NYSE:ELAN) reported strong Q1 2026 results, exceeding expectations with 10% organic constant currency revenue growth and raised full-year guidance. The company attributed this success to its "Big 6" innovation products like Zenrelia and Credelio Quattro, which are driving market share gains across both pet and farm animal health sectors. Elanco also highlighted progress in its deleveraging efforts and expects continued margin expansion through its Elanco Ascend productivity initiative.
Elanco Animal Health CEO reveals efforts to stop screwworm outbreak
Elanco Animal Health CEO Jeff Simmons discussed the company's efforts to combat a screwworm outbreak during his appearance on 'The Claman Countdown'. The discussion focused on their response to concerns surrounding the outbreak.
Elanco Is Finally Realizing Its Transformation From Caterpillar to Butterfly
Elanco, a major animal drug producer, has faced challenges in becoming a more dominant and profitable competitor despite a sound strategy focused on innovation. The firm is now beginning to realize its potential, a transformation highlighted by strong product performance. This shift is expected to improve its competitive standing and profitability in the long run.
Elanco’s stock climbs after company posts strong 1st quarter results
Elanco Animal Health's stock rose significantly after exceeding first-quarter earnings expectations and raising its full-year guidance. The company reported adjusted earnings of 35 cents per share on revenue of $1.2 billion, primarily driven by strong product sales and market share gains, particularly in its parasiticides portfolio. Elanco anticipates continued growth, especially with upcoming product launches.
Earnings call transcript: Elanco Animal Health Q1 2026 surpasses expectations with strong growth
Elanco Animal Health reported strong Q1 2026 results, exceeding analyst expectations with EPS of $0.40 and revenue of $1.371 billion, driven by innovation and market share gains. The company raised its full-year revenue and EPS guidance, reflecting confidence in its growth trajectory and the performance of its "Big Six" products. Despite inflation pressures and competitive challenges, Elanco is leveraging its diverse portfolio and strategic initiatives like Elanco Ascend to drive efficiencies and long-term value.
Elanco (NYSE: ELAN) grows Q1 2026 revenue 15% while profit declines
Elanco Animal Health (NYSE: ELAN) reported a 15% increase in Q1 2026 revenue, reaching $1,371 million, driven by strong performance in both pet health and farm animal products. Despite this top-line growth, net income declined by 15% to $57 million, with diluted EPS falling to $0.11, primarily due to higher amortization, restructuring costs, and increased interest expenses. The company also highlighted strategic advancements, including new product approvals and the acquisition of AHV International, alongside ongoing legal matters and financial stability with $428 million in cash.
Earnings Flash (ELAN) Elanco Animal Health Incorporated Posts Q1 Adjusted EPS $0.40 per Share, vs. FactSet Est of $0.35
Elanco Animal Health Incorporated (ELAN) reported Q1 adjusted EPS of $0.40 per share, surpassing the FactSet estimate of $0.35. The company also announced a Q1 revenue of $1.37 billion, exceeding the FactSet estimate of $1.28 billion. Additionally, Elanco provided upbeat guidance for Q2 and the full year 2026 for both revenue and adjusted EPS.
Global Animal Euthanasia Market to Reach $3.26 Billion by 2036,
The global animal euthanasia market is projected to reach $3.26 billion by 2036, growing at a CAGR of 6.5% from an estimated $1.74 billion in 2026, according to Fact.MR. This growth is driven by expanding veterinary infrastructure, stricter regulatory standards, and the "humanization" of companion animals. Euthanasia drugs and companion animals are expected to dominate market shares, with promising growth in emerging markets like South Africa and China.
GUIDANCE: (ELAN) Elanco Animal Health Expects 2026 Adjusted EPS Range $1.03 to $1.09, Vs. FactSet Est of $1.03
Elanco Animal Health (ELAN) has provided its adjusted EPS guidance for 2026, expecting it to be in the range of $1.03 to $1.09. This projection aligns with FactSet's estimated EPS of $1.03. The company's guidance offers insight into its financial outlook for the coming years.
Elanco Animal Health Reports First Quarter 2026 Results
Elanco Animal Health reported strong first-quarter 2026 results, with revenue increasing 15% year-over-year to $1,371 million, driven by innovation and growth in both Pet Health and Farm Animal segments. The company raised its full-year 2026 guidance for revenue, Adjusted EBITDA, and Adjusted EPS, while also improving its year-end net leverage ratio target. Key product launches like Credelio Quattro and Zenrelia contributed significantly to the outperformance, demonstrating the success of Elanco's innovation-led strategy.
Elanco (ELAN) CFO receives new deferred stock unit award
Elanco Animal Health's EVP and CFO, Robert M. VanHimbergen, was granted 8.7526 deferred stock units, each valued at $22.51. This award increases his total holdings to 74.4993 deferred stock units, which will settle in cash or company stock after employment concludes or on a specified future date as per the Executive Deferral and Stock Match Plan. This transaction is a compensation award, not an open-market purchase or sale.
Elanco (ELAN) officer awarded 65 deferred stock units under plan
Rajeev A. Modi, an officer at Elanco Animal Health Inc. (ELAN), was awarded 65.6122 deferred stock units on May 1, 2026, at a reference price of $22.51 per unit. These units represent the right to receive Elanco common stock or cash equivalent upon termination of employment or in a specified future year, under the Executive Deferral and Stock Match Plan. Following this grant, Modi directly holds a total of 9,265.6213 deferred stock units.
Elanco (NYSE: ELAN) CEO receives grant of deferred stock units as pay
Jeffrey N. Simmons, President and CEO of Elanco Animal Health (NYSE: ELAN), received a grant of 125.5855 deferred stock units on May 1, 2026, as part of his compensation. These units, valued at $22.51 each, are not an open-market trade and increase his total deferred stock unit balance to 24,164.1158. The units represent the right to receive Elanco common stock or cash equivalent upon termination of employment or in a specified future year, as per the company's Executive Deferral and Stock Match Plan.
Diagnostics, Vet Visits, Giving Pets a Voice: Jay Mazelsky & Jay Price
This article discusses the evolving landscape of pet healthcare with insights from Jay Mazelsky (CEO of IDEXX) and Jay Price (CEO of Mission Pet Health). They emphasize the growing need for senior pet care, the critical role of diagnostics in identifying diseases early, and the importance of maintaining a strong culture in the animal health industry. The piece highlights how increased pet ownership post-pandemic and advancements in diagnostics and AI are shaping the future of veterinary care, leading to longer and healthier lives for pets.
Elanco Animal Health Pays $15M to Investors After Hiding Channel Stuffing Behind Revenue Growth Claims
Elanco Animal Health has been ordered to pay $15 million to investors after the SEC found the company misled them about its revenue growth. The company engaged in "channel stuffing" from 2019 to 2020 by offering distributors incentives to purchase excess product, creating an illusion of strong demand. When Elanco ceased these practices, revenue collapsed, which the company falsely attributed to the COVID-19 pandemic.
2,461,018 Shares in Elanco Animal Health Incorporated $ELAN Bought by Artemis Investment Management LLP
Artemis Investment Management LLP has acquired a new position of 2,461,018 shares in Elanco Animal Health Incorporated, valued at approximately $55.7 million. This purchase represents about 0.50% of the company's stock and comes as analysts have shown more positive sentiment with several upgrades, giving ELAN an average "Moderate Buy" rating and a target price of $27.90. Elanco recently exceeded Q4 revenue and EPS expectations, reporting 12.2% year-over-year revenue growth and providing optimistic guidance for Q1 and FY2026.
Jennison Associates LLC Sells 1,347,898 Shares of Elanco Animal Health Incorporated $ELAN
Jennison Associates LLC reduced its stake in Elanco Animal Health Incorporated by 33.9% in the fourth quarter, selling over 1.3 million shares but still retaining a significant holding worth approximately $59.4 million. Despite this sale, several other hedge funds increased their positions in ELAN. The company reported strong Q4 earnings, beating analyst estimates, and offered positive guidance for Q1 and FY2026, leading to multiple analyst upgrades and a "Moderate Buy" consensus rating.
Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Rating of "Moderate Buy" by Brokerages
Elanco Animal Health (NYSE:ELAN) has received an average "Moderate Buy" rating from thirteen brokerages, with an average 12-month price target of $27.90. The company recently surpassed its quarterly EPS estimates and reported 12.2% revenue growth, setting optimistic guidance for Q1 and FY 2026. Despite some stock volatility, institutional ownership remains high at 97.48%, indicating strong investor confidence.
Vanguard Capital Management (ELAN) reports 26.14M shares, 5.25% stake
Vanguard Capital Management reported a beneficial ownership of 26,138,990 shares in Elanco Animal Health Inc., representing a 5.25% stake, according to a Schedule 13G filing. Vanguard holds sole dispositive power over all these shares and sole voting power over 3,802,866 shares. The filing indicates that these holdings are managed for Vanguard funds and certain client accounts.
Elanco Animal Health (ELAN) Receives a Buy from Bank of America Securities
Bank of America Securities analyst Michael Ryskin has maintained a Buy rating for Elanco Animal Health (ELAN) with a price target of $30.00. Ryskin, a 3-star analyst, has an average return of 1.0% and a 47.38% success rate, focusing on the Healthcare sector. The analyst consensus for Elanco Animal Health is currently a Strong Buy with an average price target of $29.40.
Elanco Animal Health (ELAN) to Release Quarterly Earnings on Wednesday
Elanco Animal Health (ELAN) is expected to release its Q1 2026 earnings before market open on Wednesday, May 6th, with analysts forecasting an EPS of $0.35 and revenue of $1.279 billion. The company had previously beaten estimates in its Q4 2025 report with $0.13 EPS and $1.14 billion in revenue. Analysts currently have a "Moderate Buy" rating for ELAN with an average price target of $27.90.
FDA and EPA grant emergency use of Elanco screwworm treatments
The FDA and EPA have granted emergency use authorization for Elanco's Negasunt Powder and Section 18 Emergency Exemption for Tanidil to prevent and treat New World screwworm infestations in various livestock species. These treatments will be available through USDA's APHIS National Veterinary Stockpile. The decision comes as screwworm cases have been detected close to the U.S.-Mexico border, emphasizing the need for immediate treatment options and preventative measures.
Elanco Animal Health Incorporated $ELAN Shares Sold by Skylands Capital LLC
Skylands Capital LLC significantly reduced its stake in Elanco Animal Health (NYSE:ELAN) by 27.6% in the fourth quarter, selling 81,600 shares, though institutional investors still hold a dominant position of about 97.48% of the company's stock. Despite this sell-off, Elanco reported strong Q4 earnings, beating analyst expectations with $0.13 EPS and $1.14 billion in revenue, and provided positive guidance for Q1 and FY2026. Analyst sentiment for ELAN remains largely positive, with an average "Moderate Buy" rating and a price target of $27.90.
BofA Securities Maintains Elanco Animal Health(ELAN.US) With Buy Rating, Maintains Target Price $30
BofA Securities has reiterated its Buy rating on Elanco Animal Health (ELAN.US) and has maintained its price target of $30. This indicates a continued positive outlook from the firm regarding the company's stock performance.
/C O R R E C T I O N -- Elanco Animal Health/
Elanco (NYSE: ELAN) has received Emergency Use Authorization (EUA) from the FDA for Negasunt Powder and a Section 18 Emergency Exemption from the EPA for Tanidil, both for the prevention and treatment of New World screwworm infestations in livestock. These authorizations provide critical treatment options for veterinarians and livestock producers as screwworm cases have been detected near the U.S. border. The products will be distributed through APHIS and the National Veterinary Stockpile, with strict safety protocols and use restrictions in place.
